Mortality rates for Aspergillus infections are as high as 80% (100% without treatment) and Candida remains the most common cause (over 50%) of
Clinical and Commercial Development
Novamycin is unique as the first antifungal in development for the treatment of fungal disease as an inhaled, systemic and mucocutaneous therapy. NP339 is a rapidly acting fungicidal peptide that has demonstrated superiority over existing antifungal classes in preclinical testing (with a
Novamycin is a novel, potent synthetic antimicrobial peptide (AMP) generated from NovaBiotics rational drug design technology platform. Specifically, Novamycin is a poly-Arginine based cationic peptide.
Mechanism of Action
Novamycin acts through membrane perturbation and lysis; this mode of action rapidly killing both non-metabolising and metabolically active fungi. This mechanism of action minimises or negates the risk of acquired drug resistance. Novamycin has been shown to be active against pathogens that are resistant/insensitive to conventional antifungals and has a placebo-like safety profile.
Date of article/Start date of trial: 5 October 2017